GlassScriptPhysician profile
Michael C Foster
NPI 1548224710
$3,550.70
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,583 · 2020: $965 · 2021: $1,003.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $623.54 | 2019-2021 | |
| Novo Nordisk INC | $454.84 | 2019-2021 | |
| Glaxosmithkline, LLC. | $318.93 | 2019-2021 | |
| Daiichi Sankyo INC. | $306.25 | 2019-2021 | |
| Amarin Pharma, INC. | $260.00 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.60 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $203.05 | 2019-2021 | |
| Mylan Specialty L.P. | $190.53 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.95 | 2019-2021 | |
| Pfizer INC. | $133.68 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $119.13 | 2019-2020 | |
| Amgen INC. | $114.64 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $73.64 | 2021 | |
| Abbott Laboratories | $72.94 | 2019-2021 | |
| Biogen, INC. | $44.30 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $43.75 | 2019-2020 | |
| Horizon Therapeutics Plc | $27.58 | 2021 | |
| Jazz Pharmaceuticals INC. | $26.48 | 2019-2020 | |
| Allergan, INC. | $25.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.71 | 2021 | |
| Lilly USA, LLC | $15.42 | 2019 | |
| Medtronic USA, INC. | $12.92 | 2020 | |
| Genentech USA, INC. | $12.03 | 2019 | |
| Eisai INC. | $12.02 | 2020 | |
| Abbvie INC. | $11.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.57 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.